Literature DB >> 28477729

Cardiovascular alterations in adult GH deficiency.

Carolina Di Somma1, Elisabetta Scarano2, Silvia Savastano3, Maria Cristina Savanelli4, Rosario Pivonello5, Annamaria Colao6.   

Abstract

There is a growing body of evidence indicating that patients with adult GH deficiency (GHD) are characterized by a cluster of traditional and emerging cardiovascular risk factors and markers, which can significantly increase their cardiovascular morbidity and mortality possibly linked to aberrations in GH status. Patients with adult GHD present multiple different cardiovascular abnormalities. In addition, cardiovascular risk in adult GHD is increased due to altered body composition, abnormal lipid profile, insulin resistance and impaired glucose metabolism. Cardiovascular risk factors can be reversed, at least partially, after GH replacement. However, evidence on the effects of GH replacement on cardiovascular events and mortality is too limited in adult GHD patients. Aim of this review is to provide an at-a-glance overview of the role of the GH/IGF-I on the cardiovascular system and the state of art of the effects of GH replacement on cardiovascular system.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  GH replacement therapy; body composition; cardiovascular system; growth hormone; lipid profile

Mesh:

Substances:

Year:  2017        PMID: 28477729     DOI: 10.1016/j.beem.2017.03.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  12 in total

1.  MRI Assessment of Cardiac Function and Morphology in Adult Patients With Growth Hormone Deficiency: A Systematic Review and Meta-Analysis.

Authors:  Fabio Bioletto; Nunzia Prencipe; Alessandro Maria Berton; Chiara Bona; Mirko Parasiliti-Caprino; Riccardo Faletti; Ezio Ghigo; Silvia Grottoli; Valentina Gasco
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-10       Impact factor: 6.055

2.  Association between Growth Differentiation Factor-15 and Risk of Cardiovascular Diseases in Patients with Adult Growth Hormone Deficiency.

Authors:  Xun Wu; Yunting Wang; Ziyu Ren; Linman Li; Wenjie Qian; Yue Chen; Wei Ren
Journal:  Int J Endocrinol       Date:  2021-08-06       Impact factor: 3.257

Review 3.  A Functional Interplay between IGF-1 and Adiponectin.

Authors:  Stefania Orrù; Ersilia Nigro; Annalisa Mandola; Andreina Alfieri; Pasqualina Buono; Aurora Daniele; Annamaria Mancini; Esther Imperlini
Journal:  Int J Mol Sci       Date:  2017-10-14       Impact factor: 5.923

Review 4.  Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks.

Authors:  Juan J Díez; Susana Sangiao-Alvarellos; Fernando Cordido
Journal:  Int J Mol Sci       Date:  2018-03-17       Impact factor: 5.923

Review 5.  GH Supplementation Effects on Cardiovascular Risk in GH Deficient Adult Patients: A Systematic Review and Meta-analysis.

Authors:  Vito A Giagulli; Marco Castellana; Raffaella Perrone; Edoardo Guastamacchia; Massimo Iacoviello; Vincenzo Triggiani
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2017-11-16       Impact factor: 2.895

Review 6.  Glucose Metabolism in Children With Growth Hormone Deficiency.

Authors:  Alessandro Ciresi; Carla Giordano
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-11       Impact factor: 5.555

7.  The Somatotropic Axis in the Sleep Apnea-Obesity Comorbid Duo.

Authors:  Louis-Marie Galerneau; Anne-Laure Borel; Olivier Chabre; Marc Sapene; Bruno Stach; Janie Girey-Rannaud; Renaud Tamisier; Jean-Louis Pépin; Philippe Caron
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-12       Impact factor: 5.555

8.  Somatotropic Axis and Obesity: Is There Any Role for the Mediterranean Diet?

Authors:  Giovanna Muscogiuri; Luigi Barrea; Daniela Laudisio; Carolina Di Somma; Gabriella Pugliese; Ciro Salzano; Annamaria Colao; Silvia Savastano
Journal:  Nutrients       Date:  2019-09-16       Impact factor: 5.717

9.  Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome.

Authors:  Angus P Yu; Felix N Ugwu; Bjorn T Tam; Paul H Lee; Vicki Ma; Simon Pang; Angel S Chow; Kenneth K Cheng; Christopher W Lai; Cesar S Wong; Parco M Siu
Journal:  Sci Rep       Date:  2020-03-26       Impact factor: 4.379

10.  Treatment of growth hormone attenuates hepatic steatosis in hyperlipidemic mice via downregulation of hepatic CD36 expression.

Authors:  Hyung Seok Jang; Kyeongdae Kim; Mi-Ran Lee; Shin-Hye Kim; Jae-Hoon Choi; Mi Jung Park
Journal:  Anim Cells Syst (Seoul)       Date:  2020-06-12       Impact factor: 1.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.